Hepion Pharmaceuticals files draft information statement for shareholders

• Hepion shareholder authorization covers a reverse stock split of common stock, with the board able to set a ratio from 1-for-20 to 1-for-50.
• The draft also authorizes an increase in authorized common shares to 750 million from 120 million.
• Equity incentive capacity is set to expand, lifting shares issuable under the 2023 Omnibus Equity Incentive Plan to 18 million from 8 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-040669), on August 31, 2026, and is solely responsible for the information contained therein.